What discharge planners and cardiologists need to know: our evidence-based recovery protocols, monitoring approach, and per-condition program targets.
Headline Target
The CMS national average for 30-day cardiac readmission is 17–20%. Our program targets less than half that — through intensive monitoring, nurse-led coordination, and proactive early-warning intervention.
Recovery Framework
Three structured phases take patients from acute post-discharge vulnerability to durable independence — with intensive nurse oversight calibrated to risk at each stage.
The first two weeks post-discharge carry the highest readmission risk. Daily nurse check-ins, continuous pulse oximetry via Masimo MightySat, and 6-lead ECG via KardiaMobile establish a baseline and catch deterioration before it becomes a crisis.
As hemodynamic stability is confirmed, the focus shifts to building functional capacity. Activity tolerance is advanced incrementally. Monitoring transitions from daily to every-other-day, while outcome benchmarks are tracked against program targets.
The final phase is about durable self-management. Patients learn to interpret their own monitoring data, recognize early warning signs, and manage their condition with confidence. Discharge criteria are objective and individually verified.
Per-Condition Targets
Each of our six programs is built around condition-specific evidence-based protocols. Targets reflect the outcomes our clinical methodology is designed to achieve.
Daily fluid retention screening, weight trending, and diuretic response monitoring. CHF is our highest-volume program — the national readmission rate for CHF exceeds 22%. Our protocol targets daily surveillance during weeks 1–3 to catch decompensation before it requires hospitalization.
Wound surveillance, activity restriction enforcement, and pain-vs-angina differentiation. Sternal precaution compliance is monitored through the first 6 weeks. Rhythm monitoring via KardiaMobile 6L detects post-op atrial fibrillation, a major CABG readmission driver.
Anticoagulation monitoring (warfarin/DOAC compliance), heart failure symptom screening, and activity restoration. For TAVR patients, we coordinate with the interventional team on valve function thresholds and escalation criteria.
Medication adherence (dual antiplatelet, beta-blocker, statin), activity progression against angina threshold, and psychosocial support. Post-MI depression is a readmission predictor — we screen for it explicitly and coordinate with mental health providers when flagged.
Continuous rhythm awareness via KardiaMobile 6L 6-lead ECG. Rate control monitoring, anticoagulation compliance (stroke prevention), and AF burden trending. Post-ablation and post-cardioversion patients benefit from daily rhythm checks during the blanking period.
Ejection fraction monitoring correlation, GDMT (guideline-directed medical therapy) adherence, and exertion intolerance tracking. For HCM patients, activity restriction and symptom response monitoring are central to the protocol — avoiding triggers that precipitate sudden cardiac events.
Continuous Monitoring
The evidence on cardiac readmission is clear: most preventable readmissions are preceded by 24–72 hours of detectable early warning signs. Our monitoring stack is built to find them.
Medical-grade SpO₂, pulse rate, respiration rate, and perfusion index. Fingertip form factor for at-home continuous use. Early desaturation — a CHF and post-surgical readmission predictor — is caught before the patient is symptomatic.
FDA-cleared 6-lead ECG in a pocket-sized device. Detects AFib, bradycardia, tachycardia, and 6 additional arrhythmia classifications. Used for daily rhythm checks in post-CABG, valve, and arrhythmia patients during the high-risk window.
Hospital-grade oscillometric BP monitoring for hypertension management and fluid status trending. Hypotension detection is critical for beta-blocker titration and diuretic management — the two most common medication errors post-discharge.
Premium stethoscope for S3/S4 heart sound detection, pulmonary crackle assessment, and murmur evaluation during in-home visits. S3 gallop is an early CHF decompensation sign that precedes fluid overload symptoms by 12–24 hours.
Why this matters for referring physicians: When you refer a patient to Summit Cardiac, every early warning sign detected by our monitoring stack is documented and communicated back to you. Your patients don't disappear into the community — they stay under clinical observation, and you receive updates on deterioration signals before they become readmissions that affect your CMS scores.
Our Approach
Our program is grounded in peer-reviewed cardiac nursing research and guideline recommendations from the American Heart Association and American College of Cardiology.
All monitoring thresholds, activity progression protocols, and escalation criteria are derived from AHA/ACC heart failure and post-acute cardiac care guidelines. We don't improvise — we implement what the evidence says works.
Contact frequency is not uniform — it's determined by individual readmission risk score, vital sign trajectory, and medication complexity. Higher-risk patients receive daily contact in weeks 1–4; lower-risk patients progress faster to independence.
We don't wait for patients to call with symptoms. Our monitoring triggers predefined escalation criteria: notify referring physician within 4 hours of a red flag, ED recommendation within 1 hour of a critical finding. Every escalation is documented.
Download the referral guide for everything your discharge planning team needs, or submit a patient inquiry directly.